Court Orders, Stock Price Movements, FDA Approvals and Strategic Collaborations - Research Report on Johnson & Johnson, Santarus, Salix, St. Jude Medical, and Covance PR Newswire NEW YORK, November 21, 2013 NEW YORK, November 21, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Santarus, Inc. (NASDAQ: SNTS), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), St. Jude Medical, Inc. (NYSE: STJ) and Covance Inc. (NYSE: CVD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Johnson & Johnson Research Report On November 19, 2013, Bloomberg reported that Janssen Pharmaceuticals (Janssen), a unit of Johnson & Johnson family of Companies (Johnson & Johnson), was ordered by a Philadelphia jury to pay $11 million in a case claiming that the Company's anti-seizure drug Topamax caused birth defects. According to the Bloomberg report, jurors in state court in Philadelphia found that Janssen Pharmaceuticals failed to adequately warn doctors for Haley Powell, a stay-at-home mother, of the risks of Topamax before she gave birth to a son with a cleft lip. The Bloomberg report added that Janssen lost a c.$4.0 million verdict on October 30, 2013 in a lawsuit brought by Virginia resident April Czimmer for injuries to her six-year-old son. Bloomberg reported that Janssen will appeal the verdicts in both cases. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/07a8_JNJ Santarus, Inc. Research Report On November 18, 2013, Santarus, Inc.'s (Santarus) stock rose 0.06%, ending the day at $32.12. Over the previous three trading sessions, shares of Santarus gained 0.47%, compared to the Nasdaq Composite which declined 0.42% during the same period. The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/22f8_SNTS Salix Pharmaceuticals, Ltd. Research Report On November 18, 2013, Salix Pharmaceuticals, Ltd. (Salix) announced that the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has approved Deflux premarket approval (PMA) supplement, which requested approval of labeling changes to add two additional techniques for injection, a single intra-ureteric injection (HIT procedure) and a double (proximal and distal) intra-ureteric injection (Double-HIT procedure). According to the Company, the Double-HIT procedure is a refinement of the original STING and HIT procedures and has been reported to result in greater clinical success rates. Carolyn Logan, President and CEO of Salix said, "Deflux® has always been an effective, minimally invasive option for children suffering from vesicoureteral reflux grades II-IV. This approval and update to the Deflux® labeling provides pediatric urologists even more confidence to offer Deflux to families." The Full Research Report on Salix Pharmaceuticals, Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/04fa_SLXP St. Jude Medical, Inc. Research Report On November 18, 2013, St. Jude Medical, Inc.'s (St. Jude Medical) stock declined 0.98%, ending the day at $56.81. Over the previous three trading sessions, shares of St. Jude Medical declined 1.47% compared to the S&P 500 which gained 0.53% during the same period. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/b338_STJ Covance Inc. Research Report On November 18, 2013, Covance Inc. (Covance) and NeoGenomics Inc. (NeoGenomics) announced a strategic collaboration to jointly provide anatomic pathology and specialty laboratory testing services for global clinical trials. Covance stated that through this alliance, its clients will gain access to fully integrated anatomic pathology and histology (APH) services, including immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and molecular testing. The Company stated that as part of the alliance, Covance will have access to NeoGenomics' extensive medical and scientific networks while NeoGenomics gains access to Covance's broad market reach, established client relationships, and extensive clinical trials experience. Covance added that it will develop a laboratory at NeoGenomics' Fort Myers, Florida facility and will provide a full range of APH, tissue-based biomarkers and other specialty testing services. Paul Kirchgraber, M.D., Vice President of Laboratory Operations & Medical Affairs, Covance Central Laboratory Services, said, "The collaboration with NeoGenomics will offer our clients fully integrated anatomic pathology services from sample preparation, staining and imaging, to pathology interpretation by leading pathologists, in an end-to-end manner." According to Covance, the companies will expand joint capabilities globally at Covance's central laboratory locations in Shanghai, China; Geneva, Switzerland; and Singapore. The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/5691_CVD EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.AnalystsCorner.com SOURCE Analysts' Corner Contact: Media Contact: Joe Thomas; +1-310-496-8071 (North America)
Court Orders, Stock Price Movements, FDA Approvals and Strategic Collaborations - Research Report on Johnson & Johnson,
Press spacebar to pause and continue. Press esc to stop.